GSK To Supply Combivir For NIH-Funded AIDS Trial Following Rep. Waxman Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK initially offered the HIV therapy for free but withdrew from the clinical trial in Africa after investigators revised one of three study arms, setting up a comparative effectiveness trial, Waxman says. GSK will now offer the drug at a "nonprofit," "developing country" price of 65¢ per day.